Sign In
Section Navigation
Common TitleIMEA 040 DATA
Official Title A Phase IV, Prospective, Multicenter , Randomized Open Label, 48 Weeks Study to Evaluate the Antiretroviral Efficacy and Safety of Atazanavir or Darunavir, Each in Combination With a Fixed Dose of Tenofovir Emtricitabine in HIV-1-infected Treatment-naïve Subjects With CD4 counts Below 200 µL
Phase Phase IV
ClinicalTrials.gov NCT01928407
Treatments
Darunavir
Darunavir Prezista

Darunavir

Tradename:PrezistaOther Names:DRVClass:Protease Inhibitors (PI)
,
Atazanavir
Atazanavir Reyataz

Atazanavir

Tradename:ReyatazOther Names:ATVClass:Protease Inhibitors (PI)
Categories Treatment-Naive
Funding
IndustryBristol-Myers Squibb
References
  • Slama L, Landman R, Assoumou L, et al. Efficacy and safety of once-daily ritonavir-boosted atazanavir or darunavir in combination with a dual nucleos(t)ide analogue backbone in HIV-1-infected combined ART (cART)-naive patients with severe immunosuppression: a 48 week, non-comparative, randomized, multicentre trial (IMEA 040 DATA trial). J Antimicrob Chemother. 2016;71:2252-61.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.